SEC Company Response from IRADIMED CORP (IRMD) (CIK 0001325618) (IRMD) — Jul 11, 2014
IRADIMED CORP (IRMD) (CIK 0001325618)
Date: July 11, 2014 · CIK: 0001325618 · Accession: 0001104659-14-051226
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-196875
Letter
July 11, 2014
VIA EDGAR and FACSIMILE
Amanda Ravitz
Assistant Director
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street NE
Washington, DC 20549
Re: Iradimed Corporation
Registration Statement on Form S-1
File No. 333-196875
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Iradimed Corporation, a Delaware corporation (the “Company”), hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement to become effective at 4:30 p.m., Eastern Time on Tuesday, July 15, 2014, or as soon thereafter as practicable.
The Company acknowledges that:
· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Should you have any questions or require any additional information with respect to this filing, please contact Anh Q. Tran, Esq. at (310) 552-5083 or by facsimile at (310) 552-5007.
Thank you for your assistance and cooperation.
Best regards,
IRADIMED CORPORATION
Show Raw Text
CORRESP 1 filename1.htm July 11, 2014 VIA EDGAR and FACSIMILE Amanda Ravitz Assistant Director United States Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, DC 20549 Re: Iradimed Corporation Registration Statement on Form S-1 File No. 333-196875 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Iradimed Corporation, a Delaware corporation (the “Company”), hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement to become effective at 4:30 p.m., Eastern Time on Tuesday, July 15, 2014, or as soon thereafter as practicable. The Company acknowledges that: · should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; · the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and · the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Should you have any questions or require any additional information with respect to this filing, please contact Anh Q. Tran, Esq. at (310) 552-5083 or by facsimile at (310) 552-5007. Thank you for your assistance and cooperation. Best regards, IRADIMED CORPORATION /s/ Roger E. Susi By: Roger E. Susi Title: Chief Executive Officer cc: Mary Beth Breslin, Securities and Exchange Commission Brian Soares, Securities and Exchange Commission Leib Orlanski, Esq., K&L Gates LLP Anh Q. Tran, Esq., K&L Gates LLP